What are the appropriate indications, dosing regimens, contraindications, adverse effects, and monitoring recommendations for progesterone therapy?

Progesterone Therapy: Indications, Dosing, and Clinical Guidance

Progesterone therapy has two distinct, evidence-based clinical applications: prevention of preterm birth in specific high-risk obstetric populations, and endometrial protection in menopausal hormone therapy for women with an intact uterus.

Preterm Birth Prevention

Primary Indications with Strong Evidence

For singleton pregnancies with prior spontaneous preterm birth (SPTB):

• Administer 17-alpha hydroxyprogesterone caproate (17P) 250 mg intramuscularly weekly starting at 16-20 weeks until 36 weeks 1, 2
• This reduces recurrent preterm birth by approximately 34% and decreases neonatal complications including intraventricular hemorrhage and necrotizing enterocolitis 2

For singleton pregnancies WITHOUT prior SPTB but with short cervix (≤20-25 mm) detected before 24 weeks:

• Use vaginal progesterone 90-mg gel OR 200-mg suppository daily from diagnosis until 36 weeks 1, 3
• This significantly reduces preterm birth <33 weeks (RR 0.54) and composite neonatal morbidity/mortality (RR 0.41) 1
• The most recent 2024 SMFM guideline strongly recommends vaginal progesterone for cervical length ≤20 mm, with shared decision-making for 21-25 mm 3

Populations Where Progesterone is NOT Effective

Do not use progesterone in:

• Multiple gestations (twins, triplets) - no evidence of effectiveness regardless of cervical length 1
• Active preterm labor - no benefit demonstrated 1
• Preterm premature rupture of membranes (PPROM) - no evidence of effectiveness 1
• Singleton pregnancies without prior SPTB and normal cervical length - no benefit 1

Important Nuance on 17-OHPC

The 2024 SMFM guideline recommends AGAINST 17-OHPC (including compounded formulations) for treatment of short cervix 3. This represents an evolution from earlier recommendations, as the most recent evidence (PROLONG trial) failed to demonstrate efficacy, and regulatory concerns have emerged regarding long-term safety signals 4, 5.

Menopausal Hormone Therapy

Endometrial Protection - Mandatory Indication

For women with intact uterus receiving estrogen therapy:

• Progestational agents MUST be used for minimum 10-14 days per month to prevent endometrial hyperplasia and cancer 6, 7, 6, 7, 6
• Unopposed estrogen increases endometrial cancer risk and is contraindicated in women with intact uterus 7

Dosing Options for Endometrial Protection

Cyclic regimens (10-12 days per month):

• Medroxyprogesterone acetate (MPA): 5 mg daily
• Micronized progesterone: 200 mg daily
• Norethindrone acetate: 5 mg daily 6

Continuous daily regimens:

• MPA: 2.5 mg daily
• Micronized progesterone: 100 mg daily
• Norethindrone acetate: 0.35 mg daily
• Drospirenone: 3 mg daily
• Levonorgestrel: 0.075 mg daily 6

However, continuous progesterone exposure may increase breast cancer risk and is NOT recommended 7. Long-cycle therapy (14 days every 3 months) may reduce breast exposure but lacks definitive efficacy data 7.

Alternative Routes

For women with intolerable oral progestogen side effects:

• Transdermal estradiol-progestogen patches available 6
• Transvaginal progesterone may provide adequate endometrial protection with fewer systemic effects, though data for menopausal use remain limited 6
• Levonorgestrel-releasing intrauterine system provides local endometrial protection but may increase breast cancer risk (OR 2.15 when combined with estradiol) 6

Contraindications (FDA Label)

Absolute contraindications to progesterone:

• Known hypersensitivity to progesterone or peanut oil (oral capsules contain peanut oil) 8
• Undiagnosed abnormal genital bleeding 8
• Known, suspected, or history of breast cancer 8
• Active or history of deep vein thrombosis or pulmonary embolism 8
• Active or history of arterial thromboembolism (stroke, MI) 8
• Known liver dysfunction or disease 8
• Known or suspected pregnancy (for menopausal indications) 8

Adverse Effects

Common Side Effects (Menopausal Use)

Most frequent (>10% incidence):

• Headache (31%)
• Breast tenderness (27%)
• Depression (19%)
• Dizziness (15-24%)
• Abdominal bloating (12%)
• Fatigue (8-16%) 8

Progestogen-specific symptoms:

• Premenstrual-tension-like symptoms: mood swings, bloating, fluid retention, sleep disturbance 6
• Switching among different progestational agents may reduce these symptoms 6

Serious Adverse Events (Postmarketing)

• Acute pancreatitis, cholestatic hepatitis, hepatic failure 8
• Circulatory collapse, hypertension 8
• Severe CNS effects: extreme dizziness/drowsiness, loss of consciousness, confusion, transient ischemic attack, suicidal ideation 8
• Anaphylactic reactions 8

Obstetric Use Safety Profile

Natural progesterone (vaginal, micronized) appears well-tolerated with minimal maternal side effects 9, 10. Intramuscular 17-OHPC associated with higher rate of side effects including local injection site pain, nausea, diarrhea 9. Long-term offspring safety data remain limited, particularly beyond early childhood 5.

Monitoring Recommendations

For Menopausal Hormone Therapy

Cardiovascular risk monitoring:

• Monitor lipid profiles and cardiovascular risk variables regularly 6
• Different progestogens have varying effects on lipids, insulin sensitivity, glucose tolerance, blood pressure 6

Endometrial monitoring:

• Any unexpected or abnormal vaginal bleeding requires ultrasonography and endometrial biopsy 6
• Maintain low threshold for endometrial sampling as no clear bleeding patterns predict abnormal histology 6

Bone density:

• Monitor with dual-energy x-ray absorptiometry to assess adequacy of estrogen dose for bone protection 6
• Do NOT use serum FSH levels to monitor estrogen adequacy - FSH remains elevated despite adequate tissue effects 6

For Preterm Birth Prevention

Cervical length surveillance:

• If cervix shortens to ≤25 mm by transvaginal ultrasound at <24 weeks in women already on 17P for prior SPTB, insufficient evidence exists to switch therapies - continue 17P 1
• Routine cervical length screening in women on progesterone for prior SPTB has uncertain benefit 1

Key Clinical Pitfalls

Do not confuse formulations: Natural progesterone, micronized progesterone, and synthetic progestins (17-OHPC, MPA) are NOT interchangeable and have different safety profiles 5, 11.

Do not use progesterone for active preterm labor: No evidence supports its use as primary or adjunctive tocolysis 1.

Do not prescribe 17-OHPC for short cervix: Despite earlier recommendations, current evidence does not support this indication 3.

Avoid continuous progestogen in menopausal therapy: Increased breast cancer risk with continuous exposure argues against this regimen 7.

Screen for peanut allergy: Oral progesterone capsules contain peanut oil and are absolutely contraindicated in peanut-allergic patients 8.